Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 399

1.

A synthetic cyclitol-nucleoside conjugate polyphosphate is a highly potent second messenger mimic.

Dohle W, Su X, Mills SJ, Rossi AM, Taylor CW, Potter BVL.

Chem Sci. 2019 May 2;10(20):5382-5390. doi: 10.1039/C9SC00445A. Epub 2019 Apr 23.

2.

Synthesis of Terminal Ribose Analogues of Adenosine 5'-Diphosphate Ribose as Probes for the Transient Receptor Potential Cation Channel TRPM2.

Baszczyňski O, Watt JM, Rozewitz MD, Guse AH, Fliegert R, Potter BVL.

J Org Chem. 2019 May 17;84(10):6143-6157. doi: 10.1021/acs.joc.9b00338. Epub 2019 May 7.

3.

Different substrate specificities of the two ADPR binding sites in TRPM2 channels of Nematostella vectensis and the role of IDPR.

Kühn FJP, Watt JM, Potter BVL, Lückhoff A.

Sci Rep. 2019 Mar 21;9(1):4985. doi: 10.1038/s41598-019-41531-4.

4.

Tetrahydroisoquinoline Sulfamates as Potent Microtubule Disruptors: Synthesis, Antiproliferative and Antitubulin Activity of Dichlorobenzyl-Based Derivatives, and a Tubulin Cocrystal Structure.

Dohle W, Prota AE, Menchon G, Hamel E, Steinmetz MO, Potter BVL.

ACS Omega. 2019 Jan 31;4(1):755-764. doi: 10.1021/acsomega.8b02879. Epub 2019 Jan 9.

5.

3,17β-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene and Nonsteroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structure-Activity Optimization for Isoform Selectivity.

Andring JT, Dohle W, Tu C, Potter BVL, McKenna R.

J Med Chem. 2019 Feb 28;62(4):2202-2212. doi: 10.1021/acs.jmedchem.8b01990. Epub 2019 Feb 18.

PMID:
30721041
6.

Inositol hexakisphosphate increases the size of platelet aggregates.

Brehm MA, Klemm U, Rehbach C, Erdmann N, Kolšek K, Lin H, Aponte-Santamaría C, Gräter F, Rauch BH, Riley AM, Mayr GW, Potter BVL, Windhorst S.

Biochem Pharmacol. 2019 Mar;161:14-25. doi: 10.1016/j.bcp.2018.12.011. Epub 2018 Dec 14.

7.

Small Molecule Antagonists of NAADP-Induced Ca2+ Release in T-Lymphocytes Suggest Potential Therapeutic Agents for Autoimmune Disease.

Zhang B, Watt JM, Cordiglieri C, Dammermann W, Mahon MF, Flügel A, Guse AH, Potter BVL.

Sci Rep. 2018 Nov 13;8(1):16775. doi: 10.1038/s41598-018-34917-3.

8.

Synthetic cADPR analogues may form only one of two possible conformational diastereoisomers.

Watt JM, Thomas MP, Potter BVL.

Sci Rep. 2018 Oct 15;8(1):15268. doi: 10.1038/s41598-018-33484-x.

9.

C-3- and C-4-Substituted Bicyclic Coumarin Sulfamates as Potent Steroid Sulfatase Inhibitors.

Ganeshapillai D, Woo LWL, Thomas MP, Purohit A, Potter BVL.

ACS Omega. 2018 Sep 30;3(9):10748-10772. doi: 10.1021/acsomega.8b01383. Epub 2018 Sep 6.

10.

A Fluorescent Probe Identifies Active Site Ligands of Inositol Pentakisphosphate 2-Kinase.

Whitfield H, Gilmartin M, Baker K, Riley AM, Godage HY, Potter BVL, Hemmings AM, Brearley CA.

J Med Chem. 2018 Oct 11;61(19):8838-8846. doi: 10.1021/acs.jmedchem.8b01022. Epub 2018 Sep 19.

PMID:
30160967
11.

A synthetic diphosphoinositol phosphate analogue of inositol trisphosphate.

Riley AM, Unterlass J, Konieczny V, Taylor CW, Helleday T, Potter BVL.

Medchemcomm. 2018 Jul 1;9(7):1105-1113. doi: 10.1039/C8MD00149A. Epub 2018 Jun 4.

12.

Modes of cell death induced by tetrahydroisoquinoline-based analogs in MDA-MB-231 breast and A549 lung cancer cell lines.

Nel M, Joubert AM, Dohle W, Potter BV, Theron AE.

Drug Des Devel Ther. 2018 Jun 25;12:1881-1904. doi: 10.2147/DDDT.S152718. eCollection 2018.

13.

Simple synthesis of 32P-labelled inositol hexakisphosphates for study of phosphate transformations.

Whitfield H, Riley AM, Diogenous S, Godage HY, Potter BVL, Brearley CA.

Plant Soil. 2018 Jun;427(1-2):149-161. doi: 10.1007/s11104-017-3315-9. Epub 2017 Jun 27.

14.

SULFATION PATHWAYS: Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects.

Potter BVL.

J Mol Endocrinol. 2018 Aug;61(2):T233-T252. doi: 10.1530/JME-18-0045. Epub 2018 Apr 4. Review.

PMID:
29618488
15.

Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure.

Dohle W, Jourdan FL, Menchon G, Prota AE, Foster PA, Mannion P, Hamel E, Thomas MP, Kasprzyk PG, Ferrandis E, Steinmetz MO, Leese MP, Potter BVL.

J Med Chem. 2018 Feb 8;61(3):1031-1044. doi: 10.1021/acs.jmedchem.7b01474. Epub 2018 Jan 8.

PMID:
29227648
16.

Second messenger analogues highlight unexpected substrate sensitivity of CD38: total synthesis of the hybrid "L-cyclic inosine 5'-diphosphate ribose".

Watt JM, Graeff R, Thomas MP, Potter BVL.

Sci Rep. 2017 Nov 23;7(1):16100. doi: 10.1038/s41598-017-16388-0.

17.

Accessing simply-substituted 4-hydroxytetrahydroisoquinolines via Pomeranz-Fritsch-Bobbitt reaction with non-activated and moderately-activated systems.

Mottinelli M, Leese MP, Potter BVL.

Beilstein J Org Chem. 2017 Sep 6;13:1871-1878. doi: 10.3762/bjoc.13.182. eCollection 2017.

18.

Visualizing context-dependent calcium signaling in encephalitogenic T cells in vivo by two-photon microscopy.

Kyratsous NI, Bauer IJ, Zhang G, Pesic M, Bartholomäus I, Mues M, Fang P, Wörner M, Everts S, Ellwart JW, Watt JM, Potter BVL, Hohlfeld R, Wekerle H, Kawakami N.

Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):E6381-E6389. doi: 10.1073/pnas.1701806114. Epub 2017 Jul 17.

19.

2'-Deoxyadenosine 5'-diphosphoribose is an endogenous TRPM2 superagonist.

Fliegert R, Bauche A, Wolf Pérez AM, Watt JM, Rozewitz MD, Winzer R, Janus M, Gu F, Rosche A, Harneit A, Flato M, Moreau C, Kirchberger T, Wolters V, Potter BVL, Guse AH.

Nat Chem Biol. 2017 Sep;13(9):1036-1044. doi: 10.1038/nchembio.2415. Epub 2017 Jun 26.

20.

Ligand-induced activation of human TRPM2 requires the terminal ribose of ADPR and involves Arg1433 and Tyr1349.

Fliegert R, Watt JM, Schöbel A, Rozewitz MD, Moreau C, Kirchberger T, Thomas MP, Sick W, Araujo AC, Harneit A, Potter BVL, Guse AH.

Biochem J. 2017 Jun 16;474(13):2159-2175. doi: 10.1042/BCJ20170091.

21.

SHIP2: Structure, Function and Inhibition.

Thomas MP, Erneux C, Potter BV.

Chembiochem. 2017 Feb 1;18(3):233-247. doi: 10.1002/cbic.201600541. Epub 2017 Jan 10. Review.

PMID:
27907247
22.

A Small Molecule Inhibitor of PDK1/PLCγ1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion.

Raimondi C, Calleja V, Ferro R, Fantin A, Riley AM, Potter BV, Brennan CH, Maffucci T, Larijani B, Falasca M.

Sci Rep. 2016 May 20;6:26142. doi: 10.1038/srep26142.

23.

Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors.

El-Gamal MI, Semreen MH, Foster PA, Potter BV.

Bioorg Med Chem. 2016 Jun 15;24(12):2762-7. doi: 10.1016/j.bmc.2016.04.040. Epub 2016 Apr 22.

24.

Insights into the activation mechanism of class I HDAC complexes by inositol phosphates.

Watson PJ, Millard CJ, Riley AM, Robertson NS, Wright LC, Godage HY, Cowley SM, Jamieson AG, Potter BV, Schwabe JW.

Nat Commun. 2016 Apr 25;7:11262. doi: 10.1038/ncomms11262.

25.

Crystal Structures of Type-II Inositol Polyphosphate 5-Phosphatase INPP5B with Synthetic Inositol Polyphosphate Surrogates Reveal New Mechanistic Insights for the Inositol 5-Phosphatase Family.

Mills SJ, Silvander C, Cozier G, Trésaugues L, Nordlund P, Potter BV.

Biochemistry. 2016 Mar 8;55(9):1384-97. doi: 10.1021/acs.biochem.5b00838. Epub 2016 Feb 29.

26.

The "Other" Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry).

Thomas MP, Mills SJ, Potter BV.

Angew Chem Int Ed Engl. 2016 Jan 26;55(5):1614-50. doi: 10.1002/anie.201502227. Epub 2015 Dec 22. Review.

27.

Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol.

Shen YC, Upadhyayula R, Cevallos S, Messick RJ, Hsia T, Leese MP, Jewett DM, Ferrer-Torres D, Roth TM, Dohle W, Potter BV, Barald KF.

Br J Cancer. 2015 Oct 20;113(8):1158-67. doi: 10.1038/bjc.2015.345. Epub 2015 Oct 13.

28.

The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression.

Stengel C, Newman SP, Leese MP, Thomas MP, Potter BV, Reed MJ, Purohit A, Foster PA.

Anticancer Res. 2015 Oct;35(10):5249-61.

29.

Calcium Signalling Triggered by NAADP in T Cells Determines Cell Shape and Motility During Immune Synapse Formation.

Nebel M, Zhang B, Odoardi F, Flügel A, Potter BV, Guse AH.

Messenger (Los Angel). 2015 Jun;4(1):104-111.

30.

Designer small molecules to target calcium signalling.

Swarbrick JM, Riley AM, Mills SJ, Potter BV.

Biochem Soc Trans. 2015 Jun;43(3):417-25. doi: 10.1042/BST20140293. Review.

PMID:
26009185
31.

Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.

Thomas MP, Potter BV.

J Med Chem. 2015 Oct 8;58(19):7634-58. doi: 10.1021/acs.jmedchem.5b00386. Epub 2015 Jun 12.

32.

Estrogen O-sulfamates and their analogues: Clinical steroid sulfatase inhibitors with broad potential.

Thomas MP, Potter BV.

J Steroid Biochem Mol Biol. 2015 Sep;153:160-9. doi: 10.1016/j.jsbmb.2015.03.012. Epub 2015 Apr 2. Review.

PMID:
25843211
33.

Cyclic adenosine 5'-diphosphate ribose analogs without a "southern" ribose inhibit ADP-ribosyl cyclase-hydrolase CD38.

Swarbrick JM, Graeff R, Zhang H, Thomas MP, Hao Q, Potter BV.

J Med Chem. 2014 Oct 23;57(20):8517-29. doi: 10.1021/jm501037u. Epub 2014 Oct 1.

34.

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer.

Stengel C, Newman SP, Day JM, Chander SK, Jourdan FL, Leese MP, Ferrandis E, Regis-Lydi S, Potter BV, Reed MJ, Purohit A, Foster PA.

Br J Cancer. 2014 Jul 15;111(2):300-8. doi: 10.1038/bjc.2014.188. Epub 2014 Jun 24.

35.

Design, Synthesis, and Chemical and Biological Properties of Cyclic ADP-4-Thioribose as a Stable Equivalent of Cyclic ADP-Ribose.

Tsuzuki T, Takano S, Sakaguchi N, Kudoh T, Murayama T, Sakurai T, Hashii M, Higashida H, Weber K, Guse AH, Kameda T, Hirokawa T, Kumaki Y, Arisawa M, Potter BV, Shuto S.

Messenger (Los Angel). 2014 Jun-Dec;3(1-2):35-51. Epub 2014 Jun 1.

36.

Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors.

Dohle W, Leese MP, Jourdan FL, Chapman CJ, Hamel E, Ferrandis E, Potter BV.

ChemMedChem. 2014 Aug;9(8):1783-93. doi: 10.1002/cmdc.201402025. Epub 2014 May 12.

37.

Synthetic inositol phosphate analogs reveal that PPIP5K2 has a surface-mounted substrate capture site that is a target for drug discovery.

Wang H, Godage HY, Riley AM, Weaver JD, Shears SB, Potter BV.

Chem Biol. 2014 May 22;21(5):689-99. doi: 10.1016/j.chembiol.2014.03.009. Epub 2014 Apr 24.

38.

Synthesis, anti-tubulin and antiproliferative SAR of steroidomimetic dihydroisoquinolinones.

Leese MP, Jourdan FL, Major MR, Dohle W, Thomas MP, Hamel E, Ferrandis E, Mahon MF, Newman SP, Purohit A, Potter BV.

ChemMedChem. 2014 Apr;9(4):798-812. doi: 10.1002/cmdc.201400017. Epub 2014 Mar 5.

39.

Human genome-wide RNAi screen identifies an essential role for inositol pyrophosphates in Type-I interferon response.

Pulloor NK, Nair S, McCaffrey K, Kostic AD, Bist P, Weaver JD, Riley AM, Tyagi R, Uchil PD, York JD, Snyder SH, García-Sastre A, Potter BV, Lin R, Shears SB, Xavier RJ, Krishnan MN.

PLoS Pathog. 2014 Feb 27;10(2):e1003981. doi: 10.1371/journal.ppat.1003981. eCollection 2014 Feb. Erratum in: PLoS Pathog. 2014 Mar;10(3):e1004095. PLoS Pathog. 2014 Oct;10(10):e1004519. McCaffrey, Kathleen [added].

40.

'Click cyclic ADP-ribose': a neutral second messenger mimic.

Swarbrick JM, Graeff R, Garnham C, Thomas MP, Galione A, Potter BV.

Chem Commun (Camb). 2014 Mar 7;50(19):2458-61. doi: 10.1039/c3cc49249d. Epub 2014 Jan 23.

41.

Synthesis, antitubulin, and antiproliferative SAR of C3/C1-substituted tetrahydroisoquinolines.

Dohle W, Leese MP, Jourdan FL, Major MR, Bai R, Hamel E, Ferrandis E, Kasprzyk PG, Fiore A, Newman SP, Purohit A, Potter BV.

ChemMedChem. 2014 Feb;9(2):350-70. doi: 10.1002/cmdc.201300412. Epub 2014 Jan 16.

PMID:
24436228
42.

Cellular internalisation of an inositol phosphate visualised by using fluorescent InsP5.

Riley AM, Windhorst S, Lin HY, Potter BV.

Chembiochem. 2014 Jan 3;15(1):57-67. doi: 10.1002/cbic.201300583. Epub 2013 Dec 6.

43.

Structure-activity relationship of adenosine 5'-diphosphoribose at the transient receptor potential melastatin 2 (TRPM2) channel: rational design of antagonists.

Moreau C, Kirchberger T, Swarbrick JM, Bartlett SJ, Fliegert R, Yorgan T, Bauche A, Harneit A, Guse AH, Potter BV.

J Med Chem. 2013 Dec 27;56(24):10079-102. doi: 10.1021/jm401497a. Epub 2013 Dec 13.

44.

The enzymes of human diphosphoinositol polyphosphate metabolism.

Thomas MP, Potter BV.

FEBS J. 2014 Jan;281(1):14-33. doi: 10.1111/febs.12575. Epub 2013 Nov 5. Review.

45.

Tetrahydroisoquinolinone-based steroidomimetic and chimeric microtubule disruptors.

Leese MP, Jourdan FL, Major MR, Dohle W, Hamel E, Ferrandis E, Fiore A, Kasprzyk PG, Potter BV.

ChemMedChem. 2014 Jan;9(1):85-108, 1. doi: 10.1002/cmdc.201300261. Epub 2013 Oct 9.

46.

CD38 Structure-Based Inhibitor Design Using the N1-Cyclic Inosine 5'-Diphosphate Ribose Template.

Moreau C, Liu Q, Graeff R, Wagner GK, Thomas MP, Swarbrick JM, Shuto S, Lee HC, Hao Q, Potter BV.

PLoS One. 2013 Jun 19;8(6):e66247. doi: 10.1371/journal.pone.0066247. Print 2013.

47.

Design and synthesis of cyclic ADP-4-thioribose as a stable equivalent of cyclic ADP-ribose, a calcium ion-mobilizing second messenger.

Tsuzuki T, Sakaguchi N, Kudoh T, Takano S, Uehara M, Murayama T, Sakurai T, Hashii M, Higashida H, Weber K, Guse AH, Kameda T, Hirokawa T, Kumaki Y, Potter BV, Fukuda H, Arisawa M, Shuto S.

Angew Chem Int Ed Engl. 2013 Jun 24;52(26):6633-7. doi: 10.1002/anie.201302098. Epub 2013 May 13. No abstract available.

48.

Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling and arrhythmias in the heart evoked by β-adrenergic stimulation.

Nebel M, Schwoerer AP, Warszta D, Siebrands CC, Limbrock AC, Swarbrick JM, Fliegert R, Weber K, Bruhn S, Hohenegger M, Geisler A, Herich L, Schlegel S, Carrier L, Eschenhagen T, Potter BV, Ehmke H, Guse AH.

J Biol Chem. 2013 May 31;288(22):16017-30. doi: 10.1074/jbc.M112.441246. Epub 2013 Apr 5.

49.

Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate.

Woo LW, Wood PM, Bubert C, Thomas MP, Purohit A, Potter BV.

ChemMedChem. 2013 May;8(5):779-99. doi: 10.1002/cmdc.201300015. Epub 2013 Mar 11.

50.

Stimulation of inositol 1,4,5-trisphosphate (IP3) receptor subtypes by adenophostin A and its analogues.

Saleem H, Tovey SC, Riley AM, Potter BV, Taylor CW.

PLoS One. 2013;8(2):e58027. doi: 10.1371/journal.pone.0058027. Epub 2013 Feb 28.

Supplemental Content

Loading ...
Support Center